Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI adverse events in patients with underlying IBD who received immune checkpoint inhibitors. PATIENTS AND METHO...

Whakaahuatanga katoa

I tiakina i:
Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua: Hamzah Abu‐Sbeih, David M. Faleck, Biagio Ricciuti, Robin B. Mendelsohn, Abdul Rafeh Naqash, Justine V. Cohen, Maclean C. Sellers, Aanika Balaji, Guy Ben‐Betzalel, Hajir Ibraheim, Jiajia Zhang, Mark M. Awad, Giulia C. Leonardi, Douglas B. Johnson, David J. Pinato, Dwight H. Owen, Sarah A. Weiss, Giuseppe Lamberti, Mark P. Lythgoe, Lisa Manuzzi, Christina A. Arnold, Wei Qiao, Jarushka Naidoo, Gal Markel, Nick Powell, Sai‐Ching J. Yeung, Elad Sharon, Michael Dougan, Yinghong Wang
Hōputu: Artigo
Reo:Ingarihi
I whakaputaina: 2019
Urunga tuihono:https://doi.org/10.1200/jco.19.01674
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ipurangi

https://doi.org/10.1200/jco.19.01674

Ngā tūemi rite